The Impact of L-Arginine on Uterine Artery Resistance and Pregnancy Outcomes in Frozen Embryo Transfer for IVF Candidates with Recurrent Implantation Failure: A Clinical Trial

L-精氨酸对反复着床失败的试管婴儿候选者冷冻胚胎移植中子宫动脉阻力和妊娠结局的影响:一项临床试验

阅读:1

Abstract

BACKGROUND: Recurrent implantation failure (RIF) refers to the inability to achieve pregnancy after two or three high-quality embryo transfers, representing a significant challenge in in vitro fertilization (IVF). In these women, endometrial perfusion is diminished, and uterine artery resistance is increased. The purpose of this study was to investigate the effect of oral L-arginine on uterine artery resistance and the results of IVF in infertile women with RIF. METHODS: This clinical trial was conducted on 72 infertile women, candidates for frozen embryo transfer, with a history of two previous transfer failures, who were referred to Fatemieh Infertility Center. Patients were randomly divided into two groups of control and intervention. In addition to standard drug treatment and protocol, the intervention group received oral L-arginine supplementation (3 gr daily for 20 days), beginning from the luteal phase. Uterine artery resistance index (RI) and pulsatility index (PI) were measured using two-dimensional Doppler ultrasound. Statistical analysis was performed using SPSS software, version 26, with a significance level set at less than 5%. RESULTS: Statistical analysis revealed a significant difference in the right uterine artery RI (p=0.002), left uterine artery RI (p=0.019), clinical pregnancy rate (p=0.003), and chemical pregnancy rate (p=0.006) between the two groups. CONCLUSION: This study demonstrates that the daily administration of 3 grams of oral L-arginine for 20 days in women with RIF effectively reduces uterine resistance and increases both clinical and biochemical pregnancy rates.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。